Abstract
Schizophrenia in subjects younger than 13 years is defined as very-early-onset schizophrenia, and its prevalence is estimated at 1 in 10000, while early-onset schizophrenia occurs between 13 and 17 years, and its prevalence is about 0.5%. Only a minority of youths show a complete recovery, and the majority of patients present a moderate to severe impairment at the outset. Treatment of schizophrenia always needs both pharmacological and nonpharmacological interventions. Nonpharmacological interventions include counselling for the patients and the family, psychological support, behavioural treatments, social and cognitive rehabilitation, assistance in social and scholastic activities, enhancement of social skills and family support. Pharmacological treatment is necessary for remission and control of positive and negative symptoms. Furthermore, proper pharmacotherapy can greatly increase the efficacy of psychosocial interventions. Available literature on pharmacotherapy in children and adolescents with schizophrenia is critically reviewed, including both first-and second-generation antipsychotics. Data on efficacy and safety are reported for all the marketed atypical antipsychotics (clozapine, risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole), based on randomized, placebo-controlled studies and the most relevant open-label or naturalistic studies. Adverse effects of concern are closely analysed, such as extrapyramidal side effects and tardive dyskinesia, metabolic syndrome (including hyperglycaemia and hyperlipidaemia), weight gain, hyperprolactinaemia, hepatotoxicity, seizures, and cardiovascular and haematological adverse effects. Finally, practical guidelines for the management of specific clinical situations are provided: the first phases and the long-term approach to pharmacotherapy, the treatment refractoriness and the use of clozapine in youths, the agitated adolescent and the treatment of negative symptoms and of affective co-morbidity. Current experience indicates that, based on low rates of remission, low effect size of medications and frequent adverse effects, mainly metabolic syndrome, further research is warranted, with both randomized, placebo-controlled studies and long-term, naturalistic follow-up of large samples of patients with different age ranges.
Similar content being viewed by others
References
Madaan V, Dvir Y, Wilson DR. Child and adolescent schizophrenia: pharmacological approach. Expert Opin Pharmacother 2008 Aug; 9(12): 2053–68
Werry JS. Child and adolescent (early onset) schizophrenia: a review in light of DSM-III-R. J Autism Dev Disord 1992 Dec; 22(4): 601–24
Asarnow JR, Tompson MC, McGrath E. Annotation: childhood-onset schizophrenia: clinical and treatment issues. J Child Psychol Psychiatry 2004 Feb; 45(2): 180–94
Nicolson R, Lenane M, Singaracharlu S, et al. Premorbid speech and language impairments in childhood-onset schizophrenia: association with risk factors. Am J Psychiatry 2000 May; 157(5): 794–800
McClellan J, Breiger D, McCurry C, et al. Premorbid functioning in early-onset psychotic disorders. J Am Acad Child Adolesc Psychiatry 2003 Jun; 42(6): 666–72
Masi G, Mucci M, Pari C. Children with schizophrenia: clinical picture and pharmacological treatment. CNS Drugs 2006; 20(10): 841–66
Nicolson R, Rapoport JL. Childhood-onset schizophrenia: rare, but worth studying. Biol Psychiatry 1999 Nov 15; 46(10): 1418–28
Nicolson R, Brookner FB, Lenane M, et al. Parental schizophrenia spectrum disorders in childhood-onset and adult-onset schizophrenia. Am J Psychiatry 2003 Mar; 160(3): 490–5
McKenna K, Gordon CT, Lenane M, et al. Looking for childhood-onset schizophrenia: the first 71 cases screened. J Am Acad Child Adolesc Psychiatry 1994 Jun; 33(5): 636–44
Kumra S, Jacobsen LK, Lenane M, et al. ‘Multi-dimensionally impaired disorder’: is it a variant of very early onset schizophrenia? J Am Acad Child Adolesc Psychiatry 1998 Jan; 37(1): 91–9
Werry JS, McClellan J, Chard L. Early-onset schizophrenia, bipolar and schizoaffective disorders: a clinical follow-up study. J Am Acad Child Adolesc Psychiatry 1991 May; 30(3): 457–65
McClellan JM, Werry JS, Ham M. A follow-up study of early-onset psychosis: comparison between outcome diagnoses of schizophrenia, mood disorders and personality disorders. J Autism Dev Disord 1993 Jun; 23(2): 243–62
Maziade M, Gingras N, Rodrigue C, et al. Long-term stability of diagnosis and symptoms dimensions in a systematic sample of patients with onset of schizophrenia in childhood and early adolescence, I: nosology, sex and age at onset. Br J Psychiatry 1996 Sep; 169(3): 361–70
Maziade M, Bouchard S, Gingras N, et al. Long-term stability of diagnosis and symptoms dimensions in a systematic sample of patients with onset of schizophrenia in childhood and early adolescence, II: positive/negative distinction and childhood predictors of adult outcome. Br J Psychiatry 1996 Sep; 169(3): 371–8
Eggers C, Bunk D. The long-term course of childhood-onset schizophrenia: a 42-year follow-up. Schizophr Bull 1997; 23(1): 105–17
Hollis C. Adult outcomes of child- and adolescent-onset schizophrenia: diagnostic stability and predictive validity. Am J Psychiatry 2000 Oct; 157(10): 1652–9
Petersen L, Jeppesen P, Thorup A, et al. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ 2005 Sep 17; 331: 602
Eack SM, Greenwald DP, Hogarty SS, et al. Cognitive enhancement therapy for early course of schizophrenia: effect of a two-year randomized controlled trial. Psychiatr Serv 2009 Nov; 60(11): 1468–76
Kumra S, Oberstar JV, Sikich L, et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 2008; 34(1): 60–71
Fraguas D, Correll CU, Merchàn-Naranjo J, et al. Efficacy and safety of second generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuro-psychopharmacol. Epub 2010 Aug 9
Pool D, Bloom W, Mielke DH, et al. A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res Clin Exp 1976 Jan; 19(1): 99–104
Spencer EK, Kafantaris V, Padron-Gayol MV, et al. Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol Bull 1992; 28(2): 183–6
Spencer EK, Campbell M. Children with schizophrenia: diagnosis, phenomenology and pharmacotherapy. Schizophr Bull 1994; 20(4): 713–25
Realmuto GM, Erickson WD, Yellin AM, et al. Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am J Psychiatry 1984 Mar; 141(3): 440–2
Kumra S, Frazier J, Jacobsen LK, et al. Childhood onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996 Dec; 53(12): 1090–7
Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006 Jul; 63(7): 721–30
Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and ‘high dose’ olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 2008 Mar 1; 63(5): 221–7
Haas M, Eerdekens M, Kushner L, et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: a double-blind study. Br J Psychiatry 2009 Feb; 194(2): 158–64
Haas M, Unis AS, Armenteros J, et al. A 6-week, randomized, double blind placebo-controlled study of the efficacy and safety of risperidone in adolescent with schizophrenia. J Child Adolesc Psychopharmacol 2009 Dec; 19(6): 611–21
Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004 Jan; 29(1): 133–45
Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the treatment of early-onset schizophrenia spectrum disorder (TEOSS) study. Am J Psychiatry 2008 Nov; 165(11): 1420–31
Kryzhanovskaya L, Schulz SC, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009 Jan; 48(1): 60–70
Findling R, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008 Nov; 165(11): 1432–41
Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988 Sep; 45(9): 789–96
Meltzer HY, Alphs L, Green AI, et al., International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003 Jan; 60(1): 82–91
Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993 Jul 15; 329(3): 162–7
Frazier JA, Gordon CT, McKenna K, et al. An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1994 Jun; 33: 658–63
Kranzler H, Roofeh D, Gerbino-Rosen G, et al. Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2005 Jan; 44(1): 55–63
Sporn AL, Vermani A, Greenstein DK, et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 2007 Oct; 46(10): 1349–56
Kim Y, Kim BN, Cho SC, et al. Long-term sustained benefits of clozapine treatment in refractory early-onset schizophrenia: a retrospective study in Korean children and adolescents. Hum Psychopharmacol 2008 Dec; 23(8): 715–22
Lindenmayer JP, Eerdekens E, Berry SA, et al. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004 Aug; 65(8): 1084–9
Weiden PJ, Schooler NR, Weedon JC, et al. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry 2009; 70(10): 1397–406
Chwieduk CM, Keating GM. Paliperidone: a review of its use in the management of schizophrenia. Drugs 2010 Jul 9; 70(10): 1295–317
Canuso CM, Bossie CA, Turkoz I, et al. Paliperidone extended release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms. Schizophr Res 2009 Aug; 113(1): 56–64
Stigler KA, Erickson CA, Mullett JE, et al. Paliperidone for irritability in autistic disorder. J Child Adolesc Psychopharmacol 2010 Feb; 20(1): 75–8
McConville B, Carrero L, Sweitzer D, et al. Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. J Child Adolesc Psychopharmacology 2003 Spring; 13(1): 75–82
Dittmann RW, Meyer E, Freisleder FJ, et al. Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study. J Child Adolesc Psychopharmacol 2008 Feb; 18(1): 54–69
Ross RG, Novins D, Farley GK, et al. A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol 2003 Fall; 13(3): 301–9
Grothe DR, Calis KA, Jacobsen L, et al. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. J Clin Psychopharmacol 2000 Apr; 20(2): 220–5
Schimmelmann BG, Mehler-Wex C, Lambert M, et al. A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol 2007 Dec; 17(6): 768–78
McConville BJ, Arvanitis LA, Thyrum PT, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000 Apr; 61(4): 252–60
Blair J, Scahill L, State M, et al. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry 2005 Jan; 44(1): 73–9
Patel NC, Sierk P, Dorson PG, et al. Experience with ziprasidone [letter]. J Am Acad Child Adolesc Psychiatry 2002 May; 41(5): 495
Sallee FR, Gilbert DL, Vinks AA, et al. Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission. J Am Acad Child Adolesc Psychiatry 2003 Aug; 42(8): 902–7
Staller JA. Intramuscular ziprasidone in youth: a retrospective chart review. J Child Adolesc Psychopharmacol 2004 Winter; 14(4): 590–2
Barzman DH, DelBello MP, Forrester JJ, et al. A retrospective chart review of intramuscular ziprasidone for agitation of children and adolescents on psychiatric units: prospective studies are needed. J Child Adolesc Psychopharmacol 2007 Aug; 17(4): 503–9
Bachmann CJ, Lehr D, Theisen FM, et al. Aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review. Pharmacopsychiatry 2009 Jul; 42(4): 153–7
Bachmann CJ, Rieger-Gies A, Heinzel Gutenbrunner M, et al. Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. Ther Drug Monitor 2008 Aug; 30(4): 462–6
Findling RL, Johnson JL, McClellan J, et al. Double-blind maintenance safety and effectiveness findings from the treatment of early-onset schizophrenia spectrum (TEOSS) disorders. J Am Acad Child Adolesc Psychiatry 2010 Jun; 49(6): 583–94
Gothelf D, Apter A, Reidman J, et al. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J Neural Transm 2003; 110: 545–60
Mozes T, Ebert T, Michal SE, et al. An open label, randomized comparison of of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 2006 Aug; 16(4): 393–403
Jensen JB, Kumra S, Leitten W, et al. A comparative pilot study of second generation antipsychotics in children and adolescents with schizophrenia spectrum disorder. J Child Adolesc Psychopharmacol 2008; 18: 317–26
Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008; 69 Suppl. 4: 26–36
Jerrell JM, McIntyre RS. Adverse events in children and adolescents treated with antipsychotic medications. Hum Psychopharmacol 2008 Jun; 23(4): 283–90
Kumra S, Jacobsen LK, Lenane M, et al. Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1998 Feb; 37(2): 221–7
Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second generation of antipsychotic: a systematic review. J Child Adolesc Psychopharmacol 2007 Oct; 17(5): 647–56
Theisen FM, Linden A, Geller F, et al. Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication. J Psychiatr Res 2001 Nov–Dec; 35(6): 339–45
Baptista T, Kin NM, Beaulieu S, et al. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanism, management and research perspectives. Pharmacopsychiatry 2002 Nov; 35(6): 205–19
Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006 Jul; 45(7): 771–91
Weiss R, Dziura J, Burgert DS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004 Jun 3; 350(23): 2362–74
Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 2002 Mar; 41(3): 337–43
Fleischhacker C, Heiser P, Hennonghausen P, et al. Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. J Neural Transm 2008; 115(11): 1599–608
Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009 Oct 28; 302(16): 1765–73
Lessig MC, Shapira NA, Murphy TK. Topiramate for reversing atypical antipsychotic weight gain [letter]. J Am Acad Child Adolesc Psychiatry 2001 Dec; 40(12): 1364
Pavuluri MN, Janicak PG, Carbray J. Topiramate plus risperidone for controlling weight gain and symptoms in preschool mania. J Child Adolesc Psychopharmacol 2002 Fall; 12(3): 271–3
Wu RR, Zhao JP. Metformin addition attenuates olanzapine-induced weight gain in drug-naïve first episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 2008 Mar; 165(3): 352–8
Wu RR, Zhao JP. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008 Jan 9; 299(2): 185–93
Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004; 65 Suppl. 18: 36–46
Morrato EH, Nicol GE, Maahs D, et al. Metabolic screening in children receiving antipsychotic drug treatment. Arch Ped Adolesc Med 2010; 164: 344–51
Koller E, Malozowski S, Doraiswamy PM. Atypical antipsychotic drugs and hyperglycemia in adolescents. JAMA 2001 Nov 28; 286(20): 2547–8
Koller EA, Cross JT, Schneider B. Risperidone-associated diabetes mellitus in children. Pediatrics 2004 Feb; 113(2): 421–2
Bloch Y, Vardi O, Mendlovic S, et al. Hyperglicemia from olanzapine treatment in adolescents. J Child Adolescent Psychopharmacol 2003 Spring; 13(1): 97–102
Saito E, Kafantaris V. Can diabetes mellitus be induced by medication? J Child Adolesc Psychopharmacol 2002 Fall; 12(3): 231–6
Cohen D, Huinink S. Atypical antipsychotic-induced diabetes mellitus in child and adolescent psychiatry. CNS Drugs 2007; 21(12): 1035–8
Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002; 70: 19–26
Wudarsky M, Nicolson R, Hamburger SD, et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 1999; 9(4): 239–45
Masi G, Cosenza A, Mucci M. Prolactin levels in preschool autistic children during risperidone treatment. J Child Adolesc Psychopharmacol 2001 Winter; 11(4): 389–94
Masi G, Cosenza A, Brovedani P, et al. A three-year naturalistic study of 53 preschool children with pervasive developmental disorder treated with risperidone. J Clin Psychiatry 2003 Sep; 64(9): 1039–47
Findling RL, Kusumakar V, Daneman D, et al. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 2003 Nov; 64(11): 1362–9
Saito E, Correll CU, Gallelli K, et al. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol 2004 Fall; 14(3): 350–8
Alfaro CL, Wudarsky M, Nicolson R, et al. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol 2002; 12: 83–91
Kinon BJ, Gilmore JA, Liu H, et al. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trial. Psychoneuroendocrinology 2003 Apr; 28 Suppl. 2: 69–82
Szarfman A, Tonning JM, Levine JG, et al. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 2006 Jun; 26(6): 748–58
Oyama K, Sanno N, Tahara S, et al. Management of pituitary incidentalomas: according to a survey of pituitary incidentalomas in Japan. Semin Ultrasound CT MR 2005 Feb; 26(1): 47–50
Cohen LG, Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol 2001 Winter; 11(4): 435–40
Wahl R, Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry 2005 Aug; 162(8): 1542–3
Ty EB, Rothner AD. Neuroleptic malignant syndrome in children and adolescents. J Child Neurol 2001 Mar; 16(3): 157–63
Silva RR, Munoz DM, Alpert M, et al. Neuroleptic malignant syndrome in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999 Feb; 38(2): 187–94
Sachdev P, Kruk J, Kneebone M, et al. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol 1995 Oct; 15(5): 365–71
Palakurthi HB, Parvin MM, Kaplan S. Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient. Clin Neuropharmacol 2007 Jan–Feb; 30(1): 47–51
Gerbino-Rosen G, Roofeh D, Tompkins DA, et al. Hematologic adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry 2005 Oct; 44(10): 1024–31
Kodesh A, Finkel B, Lerner AG, et al. Dose-dependent olanzapine-associated leukopenia: three case reports. Int Clin Psychopharmacol 2001 Mar; 16(2): 117–9
Ruhé HG, Becker HE, Jessurun P, et al. Agranulocytosis and granulocytopenia associated with quetiapine. Acta Psychiatr Scand 2001 Oct; 104(4): 311–3
Sporn A, Gogtay N, Ortiz-Aguayo R, et al. Clozapine-induced neutropenia in children: management with lithium carbonate. J Child Adolesc Psychopharmacol 2003 Fall; 13(3): 401–4
Gagliano A, Masi G. Clozapine-aripiprazole association in a 7-year old girl with schizophrenia and successful management of neutropenia with lithium. J Child Adolesc Psychopharmacol 2009 Oct; 19(5): 595–8
Kumra S, Herion D, Jacobsen LK, et al. Case study: risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 1997 May; 36(5): 701–5
Woods SW, Martin A, Spector SG, et al. Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry 2002 Dec; 41(12): 1409–11
Szigethy E, Wiznitzer M, Branicky LA, et al. Risperidone-induced hepatotoxicity in children and adolescents? A chart review. J Child Adolesc Psychopharmacol 1999; 9(2): 93–8
Centorrino F, Price BH, Tuttle M, et al. EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiatry 2002 Jan; 159(1): 109–15
Freedman J, Wirshing W, Russel A, et al. Absence status seizures after successful long-term clozapine treatment of an adolescent with schizophrenia. J Child Adolesc Psychopharmacol 1994; 4: 53–62
Labellarte MJ, Crosson JE, Riddle MA. The relevance of prolonged QTc measurement to pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2003 Jun; 42(6): 642–50
DelBello MP, Versavel M, Ice K, et al. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. J Child Adolesc Psychopharmacol 2008 Oct; 18(5): 491–9
Ronaldson KJ, Taylor AJ, Fitzgerald PB, et al. Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psychiatry 2010; 71(8): 982–3
Calderoni D, Wudarsky M, Bhangoo R, et al. Differentiating childhood-onset schizophrenia from psychotic mood disorders. J Am Acad Child Adolesc Psychiatry 2001 Oct; 40(10): 1190–6
Masi G, Perugi G, Millepiedi S, et al. Pharmacological response in juvenile bipolar disorder subtypes: a naturalistic retrospective examination. Psychiatry Res 2010 May; 177(1–2): 192–8
Asarnow JR. Childhood-onset schizotypal disorder: a follow-up study and comparison with childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 2005 Jun; 15(3): 395–402
Masi G, Pfanner C, Millepiedi S, et al. Aripiprazole augmentation in 39 adolescents with treatment refractory obsessive-compulsive disorder. J Clin Psychopharmacol 2010 Dec; 30(6): 688–93
Sporn AL, Addingtron AM, Gogtay N, et al. Pervasive developmental disorder and childhood-onset schizophrenia: comorbid disorder or a phenotypic variant of a very early onset illness? Biol Psychiatry 2004 May; 55(10): 989–94
Kaufman J, Birmaher B, Breslau D, et al. Kiddie-SADS — Present and Lifetime Version (K-SADS-PL). Pittsburgh: University of Pittsburgh, School of Medicine, Oct 1996 [online]. Available from URL: http://www.wpic.pitt.edu/ksads/ksads-pl.pdf [Accessed 2010 Dec 16]
Andreasen N. The scale for the assessment of positive and negative symptoms (SAPS and SANS). Iowa City (IA): Iowa University Press, 1984
Kay SR, Fiszbain Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76
Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799–812
Meehl PE. Schizotaxia, schizotypy, schizophrenia. Am Psychol 1962; 17: 827–38
Tsuang MT, Stone WS, Faraone SV. Towards the prevention of schizophrenia. Biol Psychiatry 2000 Sep 1; 48(5): 349–56
Schultze-Lutter F, Rurhmann S, Berning J, et al. Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr Bull 2010 Jan; 36(1): 182–91
McGorry PD, Nelson B, Amminger GP, et al. Intervention in individuals at ultrahigh risk for psychosis: a review and future directions. J Clin Psychiatry 2009 Sep; 70(9): 1206–12
Tsuang MT, Stone WS, Seidman LJ, et al. Treatment of non-psychotic relatives of patients with schizophrenia: four cases studies. Biol Psychiatry 1999 Jun 1; 45(11): 1412–8
Cannon TD, Huttunen MO, Dahlstrom M, et al. Antipsychotic drug treatment in the prodromal phase of schizophrenia. Am J Psychiatry 2002 Jul; 159(7): 1230–2
McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trials of interventions designed to reduce the risk of progression to the first episode of psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002 Oct; 59(10): 921–8
Koenigsberg HW, Reynolds D, Goodman M, et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 2003 Jun; 64(6): 628–34
Woods SW, Breier A, Zipursky RB, et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 2003 Aug 15; 54(4): 453–64
Fusar-Poli P, Valmaggia L, McGuire P. Can antidepressants prevent psychosis? Lancet 2007 Nov 24; 370(9601): 1746–8
Amminger GP, Berger GE, Schafer MR, et al. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry 2007 Feb 15; 61(4): 551–3
Loebel AD, Lieberman JA, Alvir JM, et al. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992 Sep; 149(9): 1183–8
Caine ED. Clinical perspectives on atypical antipsychotics for treatment of agitation. J Clin Psychiatry 2006; 67 Suppl. 10: 22–31
Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J 2003 Jul; 20(4): 339–46
Khan SS, Mican LM. A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents. J Child Adolesc Psychopharmacol 2006 Dec; 16(6): 671–7
Englisch S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Progr Neuropsychopharmacol Biol Psychiatry 2008 Aug 1; 32(6): 1386–92
Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: a 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008 May; 69(5): 720–31
Evins A, Goff D. Adjunctive antidepressant drug therapies in the treatment of negative symptoms of schizophrenia. CNS Drugs 1996; 6: 130–47
Jockers-Scherübl MC, Bauer A, Godemann F, et al. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. Int Clin Psychopharmacol 2005 Jan; 20(1): 27–31
Abbasi SH, Behpournia H, Ghoreshi A, et al. The effect of mirtazapine add-on therapy to risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Schizophr Res 2010 Feb; 116(2–3): 101–6
Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999 Jan; 56(1): 29–36
Tsai GE, Yang P, Chung LC, et al. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 1999 Nov; 156(11): 1822–5
Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and metaanalysis. Schizophr Res 2005 Jan1; 72(2–3): 225–34
Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007 Oct; 164(10): 1593–602
Sanfilipo M, Wolkin A, Angrist B, et al. Amphetamine and negative symptoms of schizophrenia. Psychopharmachology (Berl) 1996 Jan; 123(2): 211–4
Bodkin JA, Siris SG, Bermanzohn PC, et al. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiatry 2005 Feb; 162(2): 388–90
Levkovitz Y, Mendlovich S, Riwkes S, et al. A doubleblind, randomized study of minoclycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010 Feb; 71(2): 138–49
Lerner V, Libov I, Kotler M, et al. Combination of atypical antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004 Jan; 28(1): 89–98
Goodwin G, Fleischhacker W, Arango C, et al. Advantages and disadvantages of combination treatment with antipsychotics. ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 2009 Jul; 19(7): 520–32
Wolff-Menzler C, Hasan A, Malchow B, et al. Combination therapy in the treatment of schizophrenia. Pharmacopsychiatry 2010 Jun; 43(4): 122–9
Zink M, Englisch S, Meyer-Lindenbergh A. Polypharmacy in schizophrenia. Curr Opin Psychiatry 2010 Mar; 23(2): 103–11
Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a metaanalysis. Acta Psychiatrica Scand 2001 Sep; 104(3): 163–72
Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 2009 Apr; 109(1–3): 10–4
Whitehead C, Moss S, Cardino A. Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev 2002; (2): CD002035
Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther 2004 Dec; 26(12): 1994–2002
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotics in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353(12): 1209–23
Albers LJ, Ozdemir V. Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics. Curr Med Chem 2004 Feb; 11(3): 297–312
Acknowledgements
No sources of funding were used in the preparation of this review. Dr Liboni has no conflicts of interest that are relevant to the content of this review. Dr Masi is a consultant for Eli Lilly, Shire and Novartis, has received research grants from Eli Lilly, and has been a speaker for Eli Lilly, GlaxoSmithKline, Sanofi-Aventis, Janssen Cilag and AstraZeneca.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Masi, G., Liboni, F. Management of Schizophrenia in Children and Adolescents. Drugs 71, 179–208 (2011). https://doi.org/10.2165/11585350-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11585350-000000000-00000